DOCSLIB.ORG

Exenatide Appears to Be the Eti- Sessing Insulin Sensitivity from the Oral Polyposis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Exenatide Appears to Be the Eti- Sessing Insulin Sensitivity from the Oral Polyposis Letters Nolan JJ: A model-based method for as- ease, rheumatoid arthritis, and colonic in which exenatide appears to be the eti- sessing insulin sensitivity from the oral polyposis. He was taking metformin at ologic agent. A review of the literature glucose tolerance test. Diabetes Care 24: 500 mg p.o., a.c., b.i.d.; pioglitazone at 30 failed to reveal any previously reported 539–548, 2001 mg p.o. daily; NPH insulin at 45 units cases of exenatide-induced acute pancre- 20. Mita S, Kobayashi N, Yoshida K, Nakano s.q., a.c., in the morning, and 20 units atitis. An occult etiology for the pancre- S, Matsuoka H: Cardioprotective mecha- nisms of Rho-kinase inhibition associated s.q., a.c., in the evening; insulin aspart on atitis cannot be completely discounted. with eNOS and oxidative stress-LOX-1 a sliding scale; metoprolol at 50 mg p.o. Pancreatitis has been reported with meva- pathway in Dahl salt-sensitive hyperten- daily; gabapentin at 1,200 mg p.o. daily; cor, infliximab, and gabapentin, but their sive rats. J Hypertens 23:87–96, 2005 lovastatin at 40 mg p.o. daily; irbesartan protracted use without change in dose 21. Martin D, Rojo AI, Salinas M, Diaz R, Gal- at 150 mg p.o. at bedtime; clopidogrel at mitigates their being the etiologic agent. lardo G, Alam J, De Galarreta CM, 75 mg p.o. daily; infliximab at 3 mg/kg The temporal relation of the symptoms to Cuadrado A: Regulation of heme oxygen- i.v. every 8 weeks; ezetimibe 10 mg p.o. the onset and cessation of therapy along ase-1 expression through the phosphati- daily; and esomeprazole at 40 mg p.o. with the normalization of laboratory pa- dylinositol 3-kinase/Akt pathway and the daily. Remarkable findings on examina- rameters on drug withdrawal implicates Nrf2 transcription factor in response to tion were exogenous obesity, bilateral ret- exenatide as the cause. Caution should be the antioxidant phytochemical carnosol. J Biol Chem 279:8919–8929, 2004 inal dot hemorrhages, trace pitting exercised when prescribing exenatide 22. Avogaro A, Pagnin E, Calo L: Monocyte bipedal edema, hyperpigmentation of the with agents known to cause pancreatitis NADPH oxidase subunit p22(phox) and legs, and a symmetric distal stocking and in patients at high risk. inducible hemeoxygenase-1 gene expres- polyneuropathy. The patient was 6 ft tall sions are increased in type II diabetic pa- and weighed 268 lb. HbA1c level was PAUL S. DENKER, MD, FACE tients: relationship with oxidative stress. 10.5%. PAUL E. DIMARCO, MD J Clin Endocrinol Metab 88:1753–1759, Treatment options were discussed, 2003 and exenatide at 5 mg s.q. b.i.d. was ini- From the Largo HCA Diabetes Center, Clearwater, 23. Pagnin E, Fadini G, de Toni R, Tiengo A, Florida. tiated. The pioglitazone and the met- Address correspondence to Dr. Paul S. Denker, Calo L, Avogaro A: Diabetes induces formin were discontinued. Within 24 h of p66shc gene expression in human pe- MD, FACE, Largo HCA Diabetes Center, 1300 South Fort Harrison, Clearwater, Florida 33756. E- ripheral blood mononuclear cells: rela- initiating the exenatide, the patient devel- oped a midepigastric abdominal pain that mail: [email protected]. tionship to oxidative stress. J Clin © 2006 by the American Diabetes Association. Endocrinol Metab 90:1130–1136, 2005 radiated through to the back. As he con- tinued with the exenatide therapy the ●●●●●●●●●●●●●●●●●●●●●●● pain intensified. There was no fever or References chills. He denied alcohol use or exposure 1. Kendall DM, Riddle MC, Rosenstock J, Exenatide to new medication. There was no previ- Zhuang D, Kim DD, Fineman MS, Baron (Exendin-4)–Induced ous history of pancreatitis or gallstones. AD: Effects of exenatide (Exendin-4) on The patient presented to the emer- glycemic control over 30 weeks in pa- Pancreatitis gency room on the 5th day of therapy. He tients with type 2 diabetes treated with was noted to have a glucose level of 309 metformin and a sulfonylurea. Diabetes Care 28:1083–1091, 2005 A case report mg/dl, creatinine of 1.0 mg/dl, and CO2 of 27, and ketones were negative. Aspartate aminotransferase was 25 IU/l and alanine xenatide is a 39–amino acid peptide aminotransferase 25 IU/l. Serum triglyc- approved for the adjunctive treat- erides were 150 mg/dl, serum calcium The Use of Insulin E ment of type 2 diabetes. It is an in- was 8.6 mg/dl, white blood cell count was Glargine With cretin mimetic agent that is consistent in 11,000, and hemoglobin was 13.8 g/l. Se- Gestational Diabetes activity with the actions of glucagon-like rum amylase was 384 IU/l and serum peptide 1. Proposed mechanisms of ac- lipase 346 IU/l. Computed axial tomogra- Mellitus tion include enhanced glucose- phy scan of the abdomen revealed no ev- dependent insulin secretion from idence of cholelithiasis. The presumptive e agree with the recent letter by pancreatic ␤-cells, restoration of first- diagnosis of acute pancreatitis was made. Woolderink et al. (1) that insulin phase insulin response, suppression of Intravenous fluids along with intravenous W glargine use during pregnancy glucagon secretion, and delay of gastric pantoprazole were started. He was made may be appropriate. In contrast to that emptying. Kendall et al. (1) found no ev- NPO (nothing to eat), and a gastroenter- letter, which described the use of insulin idence of cardiovascular, pulmonary, he- ologic consultation was obtained. The glargine in pregnant women with type 1 patic, or renal toxicities with exenatide. NPH and the exenatide were withheld. A diabetes, we detail the use of insulin Nausea (39–48%) and hypoglycemia weight-based sliding scale of insulin was glargine in four patients with gestational (19–27%) were the most common side started using aspart. diabetes mellitus (GDM). Target blood effects reported. On subsequent days the lipase was glucose levels set by the American College A 69-year-old man with type 2 diabe- 106, 27, and 17 IU/l. The abdominal pain of Obstetricians and Gynecologists for tes of 15 years’ duration presented for fol- resolved by day 3. Clear fluids were women with GDM include fasting glucose low-up. He had known diabetic started, and the diet was advanced with- Յ95 mg/dl and 1-h postprandial glucose neuropathy and retinopathy. His medical out difficulty. The patient was discharged Յ130–140 mg/dl or 2-h postprandial history was remarkable for coronary ar- home without sequelae. glucose Յ120 mg/dl (2). These criteria tery disease, gastroesophageal reflux dis- We report a case of acute pancreatitis are used by the Maternal-Fetal Medicine DIABETES CARE, VOLUME 29, NUMBER 2, FEBRUARY 2006 471.
Load more

Recommended publications
  • Exenatide QW: a New Treatment Option for Type 2 Diabetes Offering Ease of Use, Improved Efficacy, and Reduced Side Effects
    FEATURE ARTICLE Commentary: Exenatide QW: A New Treatment Option for Type 2 Diabetes Offering Ease of Use, Improved Efficacy, and Reduced Side Effects Charles F. Shaefer, Jr., MD Editor’s note: Once-weekly exenatide, (also called incretin mimetics) cur- with GLP-1 receptor agonists is the which has recently been approved for rently in use.3,4 only form of anti-diabetes therapy patients with type 2 diabetes, has great Validation of the acceptance offering proven weight loss. Finally, potential as a new diabetes therapy in clinical practice of GLP-1 GLP-1 receptor agonist therapy is in the primary care setting. This receptor agonists can be found in one of the recommended treatment commentary and the feature article that the recently released American strategies offering a low incidence of follows it (p. 95) offer an overview of Diabetes Association (ADA)/ hypoglycemia, an important aspect this new therapeutic tool and important European Association for the Study of diabetes therapy learned from the insights about its clinical utility. In the of Diabetes (EASD) position state- Action to Control Cardiovascular interest of transparency, however, we ment on the management of type 2 Risk in Diabetes trial.6 want to point out that the authors of diabetes, which placed these drugs As clinicians consider what to do both articles are affiliated with Amylin alongside older, well-accepted agents when metformin and lifestyle change Pharmaceuticals, which manufactures such as sulfonylureas (SUs) and do not adequately control a patient’s exenatide QW and markets it under the thiozolidinediones (TZDs) as a sec- A1C, they frequently ask, “incretin 5 trade name Bydureon.
    [Show full text]
  • GLP-1 Receptor Agonists
    Cognitive Vitality Reports® are reports written by neuroscientists at the Alzheimer’s Drug Discovery Foundation (ADDF). These scientific reports include analysis of drugs, drugs-in- development, drug targets, supplements, nutraceuticals, food/drink, non-pharmacologic interventions, and risk factors. Neuroscientists evaluate the potential benefit (or harm) for brain health, as well as for age-related health concerns that can affect brain health (e.g., cardiovascular diseases, cancers, diabetes/metabolic syndrome). In addition, these reports include evaluation of safety data, from clinical trials if available, and from preclinical models. GLP-1 Receptor Agonists Evidence Summary GLP-1 agonists are beneficial for patients with type 2 diabetes and obesity. Some evidence suggests benefits for Alzheimer’s disease. It is unclear whether it is beneficial for individuals without underlying metabolic disease. Semaglutide seems to be most effective for metabolic dysfunction, though liraglutide has more preclinical data for Alzheimer’s disease. Neuroprotective Benefit: Evidence from many preclinical studies and a pilot biomarker study suggest some neuroprotective benefits with GLP-1 agonists. However, whether they may be beneficial for everyone or only a subset of individuals (e.g. diabetics) is unclear. Aging and related health concerns: GLP-1 agonists are beneficial for treating diabetes and cardiovascular complications relating to diabetes. It is not clear whether they have beneficial effects in otherwise healthy individuals. Safety: GLP-1 agonists are generally safe for most people with minor side effects. However, long-term side effects are not known. 1 Availability: Available Dose: Varies - see Chemical formula: C172H265N43O51 (Liraglutide) as a prescription chart at the end of MW: 3751.262 g/mol medicine.
    [Show full text]
  • The Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor by Peptide and Non-Peptide Ligands
    The Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor by Peptide and Non-Peptide Ligands Clare Louise Wishart Submitted in accordance with the requirements for the degree of Doctor of Philosophy of Science University of Leeds School of Biomedical Sciences Faculty of Biological Sciences September 2013 I Intellectual Property and Publication Statements The candidate confirms that the work submitted is her own and that appropriate credit has been given where reference has been made to the work of others. This copy has been supplied on the understanding that it is copyright material and that no quotation from the thesis may be published without proper acknowledgement. The right of Clare Louise Wishart to be identified as Author of this work has been asserted by her in accordance with the Copyright, Designs and Patents Act 1988. © 2013 The University of Leeds and Clare Louise Wishart. II Acknowledgments Firstly I would like to offer my sincerest thanks and gratitude to my supervisor, Dr. Dan Donnelly, who has been nothing but encouraging and engaging from day one. I have thoroughly enjoyed every moment of working alongside him and learning from his guidance and wisdom. My thanks go to my academic assessor Professor Paul Milner whom I have known for several years, and during my time at the University of Leeds he has offered me invaluable advice and inspiration. Additionally I would like to thank my academic project advisor Dr. Michael Harrison for his friendship, help and advice. I would like to thank Dr. Rosalind Mann and Dr. Elsayed Nasr for welcoming me into the lab as a new PhD student and sharing their experimental techniques with me, these techniques have helped me no end in my time as a research student.
    [Show full text]
  • LANTUS® (Insulin Glargine [Rdna Origin] Injection)
    Rev. March 2007 Rx Only LANTUS® (insulin glargine [rDNA origin] injection) LANTUS® must NOT be diluted or mixed with any other insulin or solution. DESCRIPTION LANTUS® (insulin glargine [rDNA origin] injection) is a sterile solution of insulin glargine for use as an injection. Insulin glargine is a recombinant human insulin analog that is a long-acting (up to 24-hour duration of action), parenteral blood-glucose-lowering agent. (See CLINICAL PHARMACOLOGY). LANTUS is produced by recombinant DNA technology utilizing a non- pathogenic laboratory strain of Escherichia coli (K12) as the production organism. Insulin glargine differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added to the C-terminus of the B-chain. Chemically, it is 21A- B B Gly-30 a-L-Arg-30 b-L-Arg-human insulin and has the empirical formula C267H404N72O78S6 and a molecular weight of 6063. It has the following structural formula: LANTUS consists of insulin glargine dissolved in a clear aqueous fluid. Each milliliter of LANTUS (insulin glargine injection) contains 100 IU (3.6378 mg) insulin glargine. Inactive ingredients for the 10 mL vial are 30 mcg zinc, 2.7 mg m-cresol, 20 mg glycerol 85%, 20 mcg polysorbate 20, and water for injection. Inactive ingredients for the 3 mL cartridge are 30 mcg zinc, 2.7 mg m-cresol, 20 mg glycerol 85%, and water for injection. The pH is adjusted by addition of aqueous solutions of hydrochloric acid and sodium hydroxide. LANTUS has a pH of approximately 4. CLINICAL PHARMACOLOGY Mechanism of Action: The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism.
    [Show full text]
  • Insulin Aspart Sanofi, If It Is Coloured Or It Has Solid Pieces in It
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Insulin aspart Sanofi 100 units/ml solution for injection in vial Insulin aspart Sanofi 100 units/ml solution for injection in cartridge Insulin aspart Sanofi 100 units/ml solution for injection in pre-filled pen 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml solution contains 100 units insulin aspart* (equivalent to 3.5 mg). Insulin aspart Sanofi 100 units/ml solution for injection in vial Each vial contains 10 ml equivalent to 1,000 units insulin aspart. Insulin aspart Sanofi 100 units/ml solution for injection in cartridge Each cartridge contains 3 ml equivalent to 300 units insulin aspart. Insulin aspart Sanofi 100 units/ml solution for injection in pre-filled pen Each pre-filled pen contains 3 ml equivalent to 300 units insulin aspart. Each pre-filled pen delivers 1-80 units in steps of 1 unit. *produced in Escherichia coli by recombinant DNA technology. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection (injection). Clear, colourless, aqueous solution. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Insulin aspart Sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above. 4.2 Posology and method of administration Posology The potency of insulin analogues, including insulin aspart, is expressed in units, whereas the potency of human insulin is expressed in international units.
    [Show full text]
  • Combining a Glucagon-Like Peptide-1 Receptor Agonist with Basal Insulin: the Why and How
    Combining a Glucagon-like Peptide-1 Receptor Agonist with Basal Insulin: The Why and How Case Study Mary is a 61 year-old female diagnosed with type 2 diabetes mellitus (T2DM) 8 years ago. She was initially managed with the combination of lifestyle modification and metformin. Since that time she was treated with a sulfonylurea, but it was discontinued due to symptomatic hypoglycemia. She was also treated with pioglitazone, but significant fluid retention led to it discontinuation. A year-and-a- half ago, basal insulin was added to her lifestyle and metformin management. She now administers 52 units (0.62 units/kg) once daily at bedtime. Since starting basal insulin, she has experienced 3 episodes of mild hypoglycemia. Since her diagnosis, Mary’s HbA1c has never been <7.0%; her current HbA1c is 7.9%. Over the past month, her fasting plasma glucose (FPG) has ranged from 103 mg/dL to 136 mg/dL and her postprandial glucose (PPG) from 164 mg/dL to 213 mg/dL. She has gained 2.6 kg since starting basal insulin and her body mass index is now 31 kg/m2. Her blood pressure is 134/82 mmHg. She experiences occasional tingling in her feet. Eye examination reveals grade 1 retinopathy. Current medications are: metformin 1000mg twice daily, basal insulin 52 units once daily at bedtime, and hydrochlorothiazide 25 mg once daily. Her family physician notes that Mary’s FPG is reasonably well-controlled, yet her HbA1c and PPG remain elevated. He is also concerned about her episodes of hypoglycemia and weight gain and the evidence indicating microvascular damage.
    [Show full text]
  • A Critical Appraisal of the Role of Insulin Analogues in the Management of Diabetes Mellitus Ralph Oiknine, Marla Bernbaum and Arshag D
    Drugs 2005; 65 (3): 325-340 REVIEW ARTICLE 0012-6667/05/0003-0325/$39.95/0 2005 Adis Data Information BV. All rights reserved. A Critical Appraisal of the Role of Insulin Analogues in the Management of Diabetes Mellitus Ralph Oiknine, Marla Bernbaum and Arshag D. Mooradian Division of Endocrinology, Department of Internal Medicine, Diabetes, and Metabolism, St Louis University School of Medicine, St Louis, Missouri, USA Contents Abstract ....................................................................................325 1. Physiology of Insulin Secretion .............................................................326 2. Conventional Insulin Preparations ..........................................................327 3. Insulin Analogues ........................................................................328 3.1 Rapid-Acting Insulin Analogues .......................................................328 3.1.1 Insulin Lispro ...................................................................328 3.1.2 Insulin Aspart ..................................................................329 3.1.3 Insulin Glulisine .................................................................329 3.1.4 Clinical Utility of Rapid-Acting Insulin Analogues ...................................330 3.2 Premixed Insulins and Insulin Analogues ................................................331 3.3 Basal Insulin Analogues ...............................................................331 3.3.1 Insulin Glargine ................................................................331
    [Show full text]
  • Predicting Immunogenicity of Peptide Drugs and Their Impurities
    Predicting Immunogenicity of Peptide Drugs and their Impurities using in Silico tools: Taspoglutide Case Study Aimee Mattei MS1, Frances Terry MPH1, Brian J Roberts PhD1, William Martin1, and Anne S De Groot MD1,2 1EpiVax, Inc.; 2Professor (Research) and Director, Institute for Immunology and Informatics, University of Rhode Island, USA Abstract What-if-Machine (WhIM) 15 Example Risk Profile for RLD A : . The peptide drug market is expected to generate $50B in revenue by 2024 but the FDA is Random Mimics the process of synthesizing High H ig h concerned about the number of impurities that may be introduced in the synthetic process. polypeptides and records theoretical Low 10 product impurities created through known . The peptide manufacturing process can result in synthesis-related impurities that can introduce Example Risk Profile for failures in the synthesis process. Random Peptides immunogenic epitopes within the amino acid sequence of the peptide, resulting in an unexpected 5 and undesired immune response against the drug. Each identified impurity is scored for Example Risk Profile for RLD B : putative T cell epitope content (EpiMatrix) Low 0 . EpiMatrix can be used to screen both the drug API sequence and its known peptide-related and cross conservation with the human Impurity Risk Score Risk Impurity impurities for the presence of putative T cell epitope content. proteome (JanusMatrix). -5 . When peptide-related impurities are unknown, the “What if Machine” (WhIM) can perform Impurities are weighted based on assumed probability of occurrence. Graphic for illustrative purposes only theoretical changes to the natural amino acid sequence of the drug substance and measure their -1 0 impact on the putative epitope content of the peptide.
    [Show full text]
  • Effects of Exenatide on Cardiac Function, Perfusion, and Energetics
    Chen et al. Cardiovasc Diabetol (2017) 16:67 DOI 10.1186/s12933-017-0549-z Cardiovascular Diabetology ORIGINAL INVESTIGATION Open Access Efects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine Weena J. Y. Chen1*, Michaela Diamant1^, Karin de Boer2, Hendrik J. Harms3, Lourens F. H. J. Robbers2, Albert C. van Rossum2, Mark H. H. Kramer1, Adriaan A. Lammertsma3 and Paul Knaapen2 Abstract Background: Multiple bloodglucose-lowering agents have been linked to cardiovascular events. Preliminary studies showed improvement in left ventricular (LV) function during glucagon-like peptide-1 receptor agonist administration. Underlying mechanisms, however, are unclear. The purpose of this study was to investigate myocardial perfusion and oxidative metabolism in type 2 diabetic (T2DM) patients with LV systolic dysfunction as compared to healthy controls. Furthermore, efects of 26-weeks of exenatide versus insulin glargine administration on cardiac function, perfusion and oxidative metabolism in T2DM patients with LV dysfunction were explored. Methods and results: Twenty-six T2DM patients with LV systolic dysfunction (cardiac magnetic resonance (CMR) derived LV ejection fraction (LVEF) of 47 13%) and 10 controls (LVEF of 59 4%, P < 0.01 as compared to patients) were analyzed. Both myocardial perfusion± during adenosine-induced hyperemia± (P < 0.01), and coronary fow reserve 15 (P < 0.01), measured by ­[ O]H2O positron emission tomography (PET), were impaired in T2DM patients as compared to healthy controls. Myocardial oxygen consumption and myocardial efciency, measured using ­[11C]acetate PET and CMR derived stroke volume, were not diferent between the groups.
    [Show full text]
  • OZEMPIC (Semaglutide) Injection, for Subcutaneous Use Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙CONTRAINDICATIONS∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ These highlights do not include all the information needed to use Personal or family history of medullary thyroid carcinoma or in patients OZEMPIC® safely and effectively. See full prescribing information with Multiple Endocrine Neoplasia syndrome type 2 (4). for OZEMPIC. Known hypersensitivity to OZEMPIC or any of the product components (4). OZEMPIC (semaglutide) injection, for subcutaneous use Initial U.S. Approval: 2017 ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙WARNINGS AND PRECAUTIONS∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Pancreatitis: Has been reported in clinical trials. Discontinue promptly if WARNING: RISK OF THYROID C-CELL TUMORS pancreatitis is suspected. Do not restart if pancreatitis is confirmed (5.2). See full prescribing information for complete boxed warning. Diabetic Retinopathy Complications: Has been reported in a clinical trial. Patients with a history of diabetic retinopathy should be monitored (5.3). In rodents, semaglutide causes thyroid C-cell tumors. It is Never share an OZEMPIC pen between patients, even if the needle is unknown whether OZEMPIC causes thyroid C-cell tumors, changed (5.4). including medullary thyroid carcinoma (MTC), in humans as Hypoglycemia: When OZEMPIC is used with an insulin secretagogue or the human relevance of semaglutide-induced rodent thyroid C- insulin, consider lowering the dose of the secretagogue or insulin to reduce cell tumors has not been determined (5.1, 13.1). the risk of hypoglycemia (5.5). OZEMPIC is contraindicated in patients with a personal or Acute Kidney Injury: Monitor renal function in patients with renal family history of MTC or in patients with Multiple Endocrine impairment reporting severe adverse gastrointestinal reactions (5.6). Neoplasia syndrome type 2 (MEN 2).
    [Show full text]
  • Exenatide: Role in Management of Type 2 Diabetes and Associated Cardiovascular Risk Factors
    Therapy in Practice Exenatide: role in management of Type 2 diabetes and associated cardiovascular risk factors Zin Z Htike1, Kamlesh Khunti2 & Melanie Davies* Practice Points Obesity in Type 2 diabetes poses a challenge in choosing the right combination of glucose-lowering agents, particularly due to the potential side effect of weight gain with many of the existing glucose-lowering medications. One of the incretin-based therapies, the glucagon-like peptide-1 analog, exenatide, is found to be a promising new agent that not only provides glucoregulatory effect in improving glycemic control without increase risk of hypoglycemia but also often results in weight loss. Treatment with exenatide results in reduction in HbA1c comparable to many of the existing glucose-lowering agents including basal insulin analog, galrgine or biphasic insulin aspart. Exenatide is of particular benefit in obese patients with Type 2 diabetes whose control in inadequate on a combination of oral glucose-lowering agents. To date, exenatide is not licensed for use in combination with insulin. SUMMARY Management of Type 2 diabetes, particularly in obese patients, is rather challenging as treatment with the majority of the available glucose-lowering t herapies is often associated with side effects of weight gain and hypoglycemia, in addition to failure to maintain durable glycemic control. The first available glucagon-like peptide-1 analog, exenatide, adds a new t herapeutic option to the currently available glucose-lowering agents for obese patients with Type 2 d iabetes. Both randomized controlled trials and retrospective observational s tudies have shown that treatment with exenatide not only improves glycemic control with a low risk of h ypoglycemia, but also results in concurrent weight loss with the additional benefit of i mprovement in cardiovascular risk factors of hypertension and hyperlipidemia.
    [Show full text]
  • A Network Meta-Analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
    Diabetes Ther DOI 10.1007/s13300-016-0155-1 REVIEW A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus Sheena Kayaniyil . Greta Lozano-Ortega . Heather A. Bennett . Kristina Johnsson . Alka Shaunik . Susan Grandy . Bernt Kartman To view enhanced content go to www.diabetestherapy-open.com Received: December 17, 2015 Ó The Author(s) 2016. This article is published with open access at Springerlink.com ABSTRACT treatment of adults with T2DM inadequately controlled on metformin monotherapy. Introduction: Exenatide is a glucagon-like Methods: A systematic literature review was peptide-1 receptor agonist (GLP-1 RA), conducted to identify randomized controlled approved for treatment of type 2 diabetes trials (RCTs) that investigated GLP-1 RAs mellitus (T2DM). There is limited direct (albiglutide, dulaglutide, exenatide, liraglutide, evidence comparing the efficacy and and lixisenatide) at approved doses in the tolerability of exenatide 2 mg once weekly United States/Europe, added on to metformin (QW) to other GLP-1 RAs. A network only and of 24 ± 6 weeks treatment duration. meta-analysis (NMA) was conducted to A Bayesian NMA was conducted. estimate the relative efficacy and tolerability of Results: Fourteen RCTs were included in the exenatide QW versus other GLP-1 RAs for the NMA. Exenatide QW obtained a statistically significant reduction in glycated hemoglobin (HbA1c) relative to lixisenatide 20 lg once daily. No other comparisons of exenatide QW Electronic supplementary material The online version of this article (doi:10.1007/s13300-016-0155-1) to other GLP-1 RAs were statistically significant contains supplementary material, which is available to for change in HbA1c.
    [Show full text]